Pular para o conteúdo
Merck
Todas as fotos(1)

Key Documents

Outros documentos

T4827

Sigma-Aldrich

Trandolapril

≥98% (HPLC), white, powder

Sinônimo(s):

(2S,3aR,7aS)-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid, Mavik

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C24H34N2O5
Número CAS:
87679-37-6
Peso molecular:
430.54
Número MDL:
MFCD00865776
Código UNSPSC:
12352200
ID de substância PubChem:
329826801
NACRES:
NA.77

Ensaio

≥98% (HPLC)

forma

powder

cor

white

solubilidade

DMSO: ≥20 mg/mL

originador

Abbott

cadeia de caracteres SMILES

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2C3CCCCC3C[C@H]2C(O)=O

InChI

1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1

chave InChI

VXFJYXUZANRPDJ-WTNASJBWSA-N

Informações sobre genes

human ... ACE(1636)

Procurando produtos similares? Visita Guia de comparação de produtos

Aplicação

Trandolapril has been used as an angiotensin-converting enzyme (ACE) inhibitor to study its effects on responsiveness of human retinal endothelial cells (HRECs) to vascular endothelial growth factor (VEGF).

Ações bioquímicas/fisiológicas

Studies have reported that trandolapril inhibits atherosclerosis1 and decreases the occurrence of atrial fibrillation2.
Trandolapril is an ACE inhibitor. Trandolapril differs from other ACE inhibitors in that it has a longer biological half-life and a high degree of lipophilicity.

Características e benefícios

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Nota de preparo

Trandolapril is soluble in DMSO at a concentration that is greater than or equal to 20 mg/ml.

Pictogramas

Health hazard
GHS08

Palavra indicadora

Danger

Frases de perigo

H360D

Classificações de perigo

Repr. 1B

Código de classe de armazenamento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Equipamento de proteção individual

Eyeshields, Gloves, type N95 (US)

Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Christian Lewinter et al.
European journal of heart failure, 13(12), 1349-1354 (2011-10-27)
Patients with acute myocardial infarction (MI) with bundle branch block (BBB) have a poor prognosis, but distinction between left (L)- and right (R)-sided BBB is seldom made in epidemiological studies. We studied long-term mortality associated with RBBB and LBBB in
Anthony A Bavry et al.
The American journal of medicine, 124(7), 614-620 (2011-05-21)
There is limited information about the safety of chronic nonsteroidal anti-inflammatory drugs (NSAIDs) in hypertensive patients with coronary artery disease. This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary
M Dendeni et al.
International journal of pharmaceutics, 438(1-2), 61-70 (2012-09-11)
Various regulatory authorities like International Conference on Harmonization (ICH), US Food and Drug Administration, Canadian Drug and Health Agency are emphasizing on the purity requirements and the identification of impurities in active pharmaceutical drugs. Qualification of the impurities is the
Michelle L O'Donoghue et al.
Clinical chemistry, 57(9), 1311-1317 (2011-07-26)
Secretory phospholipase A(2) (sPLA(2)) may contribute to atherogenesis. To date, few prospective studies have examined the utility of sPLA(2) for risk stratification in coronary artery disease (CAD). We measured plasma sPLA(2) activity at baseline in 3708 subjects in the PEACE
Piero Ruggenenti et al.
Journal of the American Society of Nephrology : JASN, 23(10), 1717-1724 (2012-09-01)
Micro- or macroalbuminuria is associated with increased cardiovascular risk factors among patients with type 2 diabetes, but whether albuminuria within the normal range predicts long-term cardiovascular risk is unknown. We evaluated the relationships between albuminuria and cardiovascular events in 1208
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica